Skip to main
MDT
MDT logo

Medtronic (MDT) Stock Forecast & Price Target

Medtronic (MDT) Analyst Ratings

Based on 41 analyst ratings
Buy
Strong Buy 29%
Buy 29%
Hold 39%
Sell 0%
Strong Sell 2%

Bulls say

The positive outlook for Medtronic's stock is supported by notable growth in its neuromodulation segment, where the company gained 240 basis points of market share, alongside mid-single-digit revenue growth driven by the successful adoption of the MiniMed 780G AID system. Additionally, Medtronic's diabetes revenues reached $694 million, reflecting a robust 10.4% year-over-year organic growth that surpassed consensus expectations. The anticipated revenue increase of 3.4-3.8% for FY25, along with a 10-11% year-over-year growth in EPS, further positions Medtronic favorably in the market as it enhances its ecosystem within the lucrative electrophysiology ablation sector.

Bears say

The negative outlook on Medtronic's stock is primarily driven by projected revenue growth slowing to the low-single digits, attributed to unsuccessful new product launches and market share losses in certain categories. Additionally, the company faces ongoing risks such as disappointing sales from key new products, a flat or declining operating margin, and adverse currency impacts, which collectively contribute to concerns about below-consensus earnings. Furthermore, the company's recent decrease in R&D expenses coupled with an increase in SG&A expenditures indicates potential challenges in maintaining competitive positioning and profitability.

Medtronic (MDT) has been analyzed by 41 analysts, with a consensus rating of Buy. 29% of analysts recommend a Strong Buy, 29% recommend Buy, 39% suggest Holding, 0% advise Selling, and 2% predict a Strong Sell.

This aggregate rating is based on analysts' research of Medtronic and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Medtronic (MDT) Forecast

Analysts have given Medtronic (MDT) a Buy based on their latest research and market trends.

According to 41 analysts, Medtronic (MDT) has a Buy consensus rating as of Jul 4, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $102.44, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $102.44, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Medtronic (MDT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.